EGFR and non-small cell lung carcinoma: Recently, pharmacological treatment of non-small cell lung cancer (NSCLC) has undergone a major change for patients with somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene.